In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Response Biomedical

This article was originally published in The Gray Sheet

Executive Summary

Rapid, on-site anthrax detection system based on the firm's RAMP technology is launched May 29. Intended for use by emergency responders, the environmental test can distinguish "between a hoax and a potentially infectious dose" in under 15 minutes, the firm claims. Vancouver-based Response hopes to place several hundred of the $10,000 systems by year-end, estimating a $500 mil. U.S. anthrax detection market within two years. The firm is in the process of signing co-marketing and distribution agreements. Separately, Response plans 510(k) submissions for CK-MB and troponin 1 analyte cardiac marker tests by the end of 2002. The RAMP reader was cleared in January for general clinical use along with a myoglobin cardiac marker test...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT016665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel